Rapid proliferation in small cell lung cancer (SCLC) may be mediated by synthesis of autocrine growth factors. Bombesin (or its mammalian homologue gastrin releasing peptide, GRP) may have autocrine function in SCLC Carney et al., 1987) but is not synthesised by the faster growing variant SCLC lines . Somatomedin-C (Sm-C)/insulin-like growth factor-I (IGF-I) is a basic peptide of 70 amino acids and MW 7.6 kD which is carried in serum by binding proteins of 40-150 kD (Underwood et al., 1986a) . It derives mainly from the liver but also from extrahepatic sites including lung (D'Ercole et al., 1984) . Function as an autocrine growth factor has been described in several cell systems, including cultured human fibroblasts (Clemmons et al., 1981) and breast carcinoma (Huff et al., 1986) . Minuto et al (1986) reported high levels of Sm-C in operative specimens of primary lung tumour tissue. All 10 samples were adeno-or squamous carcinoma; no results were given for SCLC, presumably because these patients rarely come to surgery. Two more recent studies have reported expression by a human large cell lung cancer line of genes for multiple growth factors including IGF-II but not IGF-I (Betsholtz et al., 1987) , and the presence of 'insulin-like' molecules in SCLC conditioned medium .
We have been working with a high molecular weight (>10 kD) concentrate of classic SCLC conditioned medium which is mitogenic to both classic and variant SCLC lines despite being depleted of bombesin/GRP (Macaulay et al., 1987) (Macaulay et al., 1987) . All cell lines were grown in RPMI medium with 5% foetal calf serum (FCS). The SCLC cell lines were characterised morphologically and biochemically as previously described Macaulay et al., 1987) . Tissue samples (200-500 mg) assay (RIA) with a disequilibrium (sequential reagent addition) assay system modified from a previously-described technique (Baxter et al., 1982; Teale & Marks, 1986) . The RIA used antiserum D193 (a gift from Dr S. Hampton, University of Surrey) raised in rabbits against biosynthetic Sm-C conjugated to keyhole limpet haemocyanin. Briefly, samples were incubated overnight with D193. Addition of iodinated tracer was followed by a second incubation period of 5 h. Separation of the antibody-bound fraction was achieved by polyethylene glycol-accelerated double antibody. A standard curve was prepared using dilutions of biosynthetic Sm-C (kindly donated by Ciba-Geigy). The biosynthetic material was shown to be equipotent with both purified Sm-C and diluted serum extract in its ability to bind to assay antibodies. Assay sensitivity was calculated as 0.5 ng ml-1. Pure preparations of proinsulin and IGF-II (kind gifts respectively of Dr B. Frank, Eli Lilly, Indianapolis, USA and Dr J. Zapf, Zurich, Switzerland) exhibited 0.01% and 3.1% cross-reactivity in an assay system containing only antiserum and tracer. A precision profile showed coefficients of variation of 25% at 2.5ngml-1, 19% at 5ngml-1, 13% at lOngml-1 and 11% at 20ngml-1. Samples were also assayed for soluble protein using the Bio-Rad Protein Assay. Results were expressed as Sm-C ng mg -protein (Table I) .
Immunoreactive Sm-C was detectable in all of 3 classic and I of 2 variant SCLC cell homogenates. Sm-C was also present in cell preparations from 2 of 3 non-small cell lung lines: one squamous carcinoma and one of 2 adenocarcinomas. Assay of tissue homogenates revealed Sm-C in bSCF LN=supraclavicular lymph node; one of these biopsies was the source of variant SCLC line ICR-SC17.
Br. J. Cancer (1988), 57, 91-93 all SCLC samples, including biopsies of primary tumour and lymph node metastases, one of which had given rise to the variant line ICR-SC17. Detectable levels were also found in 5 of 6 primary pulmonary squamous carcinomas and 3 of 4 adenocarcinomas (Table I) . These results are unlikely to be false positives given the specificity of the assay and the fact that sample Sm-C concentrations diluted in parallel with standard Sm-C. Weber et al. (1985) used 3H-thymidine uptake to measure mitogenicity of GRP in classic SCLC. We have adopted a similar technique to explore the role of Sm-C. Assays were performed on triplicate samples in 96-well microtitre plates. Lyophilised biosynthetic Sm-C (Amersham International, Amersham, UK) was reconstituted in 0.1 M acetic acid and diluted to working concentration and pH7 with Tris buffer and PBS. Individual wells received Sm-C in 20,yl to achieve final concentration of 0.1-500ngml-1. Wells supplemented with 20,ul PBS served as negative controls. Single cell suspensions from 4-8 day old cultures were washed in unsupplemented RPMI and resuspended in the same medium; each well received 6 x 103 cells in 170 pl. The plates were incubated for 46 h, labelled with 3H-thymidine (Amersham, 0.4,uCi in 10Il PBS per well) and incubated for a further 24h. Label incorporation into DNA was assessed by trichloroacetic acid precipitation and liquid scintillation counting. The results (mean + s.e.m. of 3 wells) were expressed as % uptake in negative control wells (see Figure 1 and Table II) .
Enhancement of DNA synthesis was seen in 2 of 3 classic SCLC lines, one variant, and in the faster growing of the 2 adenocarcinoma lines. Sm-C 10-100 ng ml was sufficient to cause significant stimulation (P < 0.05) of 3H-thymidine uptake. Maximal effects were seen at 100-300 ng ml -', amounting to 170-214% increase in uptake over control. These levels are of the same order as the Sm-C concentration of normal adult plasma (100-180ngml-1), although in excess of the 1-20 ng ml-concentration said to promote cell replication in other in vitro systems (Underwood et al., 1986a) . Although biosynthetic Sm-C behaves similarly to the natural peptide in most radioligand assays (Baxter et al., 1987) including our own, it may have less biological activity. (Zar, 1984) .
Response to Sm-C, which is presumably mediated by binding to Sm-C receptors (Morgan et al., 1986) , did not always correlate with cellular synthesis of the factor. Similar observations have been made regarding SCLC synthesis of, and response to, bombesin (Carney et al., 1987) . Classic SCLC lines HC12 and HX149 expressed detectable levels of, and also exhibited a mitogenic response to, Sm-C. Thus in these lines Sm-C may be functioning as an autocrine growth factor. Variant line ICR-SC17 responded to Sm-C, but had undetectable intracellular factor. Sm-C was, however, present in the tissue sample from which this line was derived, suggesting that loss of Sm-C production may have been an in vitro phenomenon. Conversely there were 3 lines (NCI-H69, classic SCLC; NCI-H226, squamous; NCI-H 125, adenocarcinoma) which expressed intracellular Sm-C but did not respond in growth assays. Lack of response here might be explained either by absence of Sm-C receptors, or alternatively by saturation of existing binding sites by endogenous factor. Studies are currently in progress to clarify this point.
Other workers have assessed the effects of somatomedins on growth of lung cancer cell lines (Simms et al., 1980; Brower et al., 1986) . Three factors may have contributed to their negative results. First, the factor used was multiplication-stimulating activity (rat IGF-II; Marquardt et al., 1981) rather than human Sm-C/IGF-I. Secondly, tests were carried out in the presence of insulin which might have activated Sm-C receptors either by direct binding (Morgan et al., 1986) or by inducing phosphorylation of the unoccupied Sm-C receptor ('cross-talk'; Taylor, 1986) . Finally, the SCLC line chosen for testing (Simms et al., 1980) was NCI-H69, which was the only one of 4 SCLC lines we assessed which failed to respond to human Sm-C. In a more recent study, IGF-I was shown to enhance the colony forming efficiency of normal human bronchial epithelial cells and newly cultured lung adenosquamous carcinoma cells. Established lung cancer cell lines had not been tested (Siegfried, 1987) . We have not yet examined the effect of Sm-C in combination with GRP, but note that Weber et al. (1985) , in studying the mitogenicity of GRP in SCLC, performed assays in the presence of FCS. Results of our RIA suggest that heat-inactivated FCS provides 40 ng ml-1 immunoreactive Sm-C.
To assess the value of Sm-C as a clinical marker in lung cancer, we assayed sera from 18 SCLC and 6 non-SCLC patients (data not shown). No results were above the normal range; it has been suggested that serum Sm-C levels are more closely related to nutritional status (Minuto et al., 1986; Underwood et al., 1986b) .
In summary, we have shown that immunoreactive Sm-C is detectable in primary and metastatic SCLC tissue and in SCLC cell lines. Biosynthetic Sm-C is mitogenic as shown by enhancement of 3H-thymidine uptake in classic and variant SCLC. Most non-small cell lung cancer tissues expressed * detectable Sm-C. However, none of the non-SCLC lines both synthesised Sm-C and responded to biosynthetic factor in growth assays. We conclude that Sm-C may function as an autocrine growth factor in SCLC. The finding of Sm-C in fresh tumour tissue suggests that this phenomenon may be relevant in vivo and offers the potential for new approaches to therapy. Tumour growth might be inhibited by immunological means, by antibodies directed against Sm-C (Russell et al., 1984) or its receptor (Conover et al., 1986) or pharmacologically, using growth factor analogues or inhibitors of secretion.
